PortalPublikationenConcurrent detection of minimal residual disease (MRD) in ch...

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR

Standard

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. / Kerst, Gunter; Kreyenberg, Hermann; Roth, Carmen; Well, Catrin; Dietz, Klaus; Coustan-Smith, Elaine; Campana, Dario; Koscielniak, Ewa; Niemeyer, Charlotte; Schlegel, Paul G; Müller, Ingo; Niethammer, Dietrich; Bader, Peter.

in: BRIT J HAEMATOL, Jahrgang 128, Nr. 6, 03.2005, S. 774-82.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kerst, G, Kreyenberg, H, Roth, C, Well, C, Dietz, K, Coustan-Smith, E, Campana, D, Koscielniak, E, Niemeyer, C, Schlegel, PG, Müller, I, Niethammer, D & Bader, P 2005, 'Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR', BRIT J HAEMATOL, Jg. 128, Nr. 6, S. 774-82. https://doi.org/10.1111/j.1365-2141.2005.05401.x

APA

Kerst, G., Kreyenberg, H., Roth, C., Well, C., Dietz, K., Coustan-Smith, E., Campana, D., Koscielniak, E., Niemeyer, C., Schlegel, P. G., Müller, I., Niethammer, D., & Bader, P. (2005). Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. BRIT J HAEMATOL, 128(6), 774-82. https://doi.org/10.1111/j.1365-2141.2005.05401.x

Vancouver

Kerst G, Kreyenberg H, Roth C, Well C, Dietz K, Coustan-Smith E et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. BRIT J HAEMATOL. 2005 Mär;128(6):774-82. https://doi.org/10.1111/j.1365-2141.2005.05401.x

Bibtex

@article{a01808578cdc4927885eb033a9f8fce7,
title = "Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR",
abstract = "Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL). To be used clinically, MRD assays must be reliable and accurate. Two well-established techniques, flow cytometry (FC) and polymerase chain reaction (PCR), can detect leukaemic cells with a sensitivity of 0.01% (10(-4)). We analysed diagnostic samples of 45 ALL-patients (37 B-lineage ALL, eight T-lineage ALL) by four-colour FC and real-time PCR. Leukaemia-associated immunophenotypes, at a sensitivity of MRD detection by FC at the 0.01% level, were identified in 41 cases (91%); antigen-receptor gene rearrangements suitable for MRD detection with a sensitivity of 0.01% or better by PCR were identified in 38 cases (84%). The combined use of FC and PCR allowed MRD monitoring in all 45 patients. In 105 follow-up samples, MRD estimates by both methods were highly concordant, with a deviation factor of <5 by Bland-Altman analysis. Importantly, the concordance between FC and PCR was also observed in regenerating bone marrow samples containing high proportions of CD19(+) cells, and in samples studied 24 h after collection. We conclude that both MRD assays yield generally concordant results. Their combined use should enable MRD monitoring in virtually all patients and prevent false-negative results due to clonal evolution or phenotypic shifts.",
keywords = "Adolescent, Biomarkers, Tumor, Child, Child, Preschool, Flow Cytometry, Gene Rearrangement, T-Lymphocyte, Humans, Infant, Neoplasm, Residual, Phenotype, Polymerase Chain Reaction, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Sensitivity and Specificity",
author = "Gunter Kerst and Hermann Kreyenberg and Carmen Roth and Catrin Well and Klaus Dietz and Elaine Coustan-Smith and Dario Campana and Ewa Koscielniak and Charlotte Niemeyer and Schlegel, {Paul G} and Ingo M{\"u}ller and Dietrich Niethammer and Peter Bader",
year = "2005",
month = mar,
doi = "10.1111/j.1365-2141.2005.05401.x",
language = "English",
volume = "128",
pages = "774--82",
journal = "BRIT J HAEMATOL",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

RIS

TY - JOUR

T1 - Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR

AU - Kerst, Gunter

AU - Kreyenberg, Hermann

AU - Roth, Carmen

AU - Well, Catrin

AU - Dietz, Klaus

AU - Coustan-Smith, Elaine

AU - Campana, Dario

AU - Koscielniak, Ewa

AU - Niemeyer, Charlotte

AU - Schlegel, Paul G

AU - Müller, Ingo

AU - Niethammer, Dietrich

AU - Bader, Peter

PY - 2005/3

Y1 - 2005/3

N2 - Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL). To be used clinically, MRD assays must be reliable and accurate. Two well-established techniques, flow cytometry (FC) and polymerase chain reaction (PCR), can detect leukaemic cells with a sensitivity of 0.01% (10(-4)). We analysed diagnostic samples of 45 ALL-patients (37 B-lineage ALL, eight T-lineage ALL) by four-colour FC and real-time PCR. Leukaemia-associated immunophenotypes, at a sensitivity of MRD detection by FC at the 0.01% level, were identified in 41 cases (91%); antigen-receptor gene rearrangements suitable for MRD detection with a sensitivity of 0.01% or better by PCR were identified in 38 cases (84%). The combined use of FC and PCR allowed MRD monitoring in all 45 patients. In 105 follow-up samples, MRD estimates by both methods were highly concordant, with a deviation factor of <5 by Bland-Altman analysis. Importantly, the concordance between FC and PCR was also observed in regenerating bone marrow samples containing high proportions of CD19(+) cells, and in samples studied 24 h after collection. We conclude that both MRD assays yield generally concordant results. Their combined use should enable MRD monitoring in virtually all patients and prevent false-negative results due to clonal evolution or phenotypic shifts.

AB - Minimal (i.e. submicroscopic) residual disease (MRD) predicts outcome in childhood acute lymphoblastic leukaemia (ALL). To be used clinically, MRD assays must be reliable and accurate. Two well-established techniques, flow cytometry (FC) and polymerase chain reaction (PCR), can detect leukaemic cells with a sensitivity of 0.01% (10(-4)). We analysed diagnostic samples of 45 ALL-patients (37 B-lineage ALL, eight T-lineage ALL) by four-colour FC and real-time PCR. Leukaemia-associated immunophenotypes, at a sensitivity of MRD detection by FC at the 0.01% level, were identified in 41 cases (91%); antigen-receptor gene rearrangements suitable for MRD detection with a sensitivity of 0.01% or better by PCR were identified in 38 cases (84%). The combined use of FC and PCR allowed MRD monitoring in all 45 patients. In 105 follow-up samples, MRD estimates by both methods were highly concordant, with a deviation factor of <5 by Bland-Altman analysis. Importantly, the concordance between FC and PCR was also observed in regenerating bone marrow samples containing high proportions of CD19(+) cells, and in samples studied 24 h after collection. We conclude that both MRD assays yield generally concordant results. Their combined use should enable MRD monitoring in virtually all patients and prevent false-negative results due to clonal evolution or phenotypic shifts.

KW - Adolescent

KW - Biomarkers, Tumor

KW - Child

KW - Child, Preschool

KW - Flow Cytometry

KW - Gene Rearrangement, T-Lymphocyte

KW - Humans

KW - Infant

KW - Neoplasm, Residual

KW - Phenotype

KW - Polymerase Chain Reaction

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Sensitivity and Specificity

U2 - 10.1111/j.1365-2141.2005.05401.x

DO - 10.1111/j.1365-2141.2005.05401.x

M3 - SCORING: Journal article

C2 - 15755280

VL - 128

SP - 774

EP - 782

JO - BRIT J HAEMATOL

JF - BRIT J HAEMATOL

SN - 0007-1048

IS - 6

ER -